Double Chin Drug Is A Perfect Fit For Botox-Maker Allergan. But Is It Too Pricey?
One thing about Allergan AGN +0.26% chief executive Brent Saunders is he doesn’t waste much time. After all, he was personally involved in setting up $97 billion worth of deals last year.
The $66 billion acquisition of the company that used to be called Allergan by Saunders’ outfit, then called Actavis , closed in March. On Monday, Actavis changed its name to Allergan, a far better known corporate brand thanks to high profile aesthetic drugs like Botox, Juvederm, and Latisse, on Monday, when Saunders rang the bell at the New York Stock Exchange. Today, Allergan is announcing that it is purchasing Kythera, the maker of Kybella, a detergent that is injected into the skin in order to dissolve fat deposits that cause double chins, for $2.1 billion.
Hey, check out all the research scientist jobs. Post your resume today!
The $66 billion acquisition of the company that used to be called Allergan by Saunders’ outfit, then called Actavis , closed in March. On Monday, Actavis changed its name to Allergan, a far better known corporate brand thanks to high profile aesthetic drugs like Botox, Juvederm, and Latisse, on Monday, when Saunders rang the bell at the New York Stock Exchange. Today, Allergan is announcing that it is purchasing Kythera, the maker of Kybella, a detergent that is injected into the skin in order to dissolve fat deposits that cause double chins, for $2.1 billion.
Hey, check out all the research scientist jobs. Post your resume today!